Abstract
Objective: ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Methods: ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121). Results: High ERCC1 expression was observed in 36 (75%) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95% CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95% CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95% CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95% CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95% CI, 1.27-71.35; p = 0.028). Conclusions: This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation.
| Original language | English |
|---|---|
| Pages (from-to) | 227-234 |
| Number of pages | 8 |
| Journal | Oncology |
| Volume | 89 |
| DOIs | |
| Publication status | Published - Sep 18 2015 |
Fingerprint
Keywords
- Adjuvant concurrent chemoradiation
- Cisplatin
- ERCC1
- Head and neck cancer
- Squamous cell carcinoma
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. / Ciaparrone, Marco; Caspiani, Orietta; Bicciolo, Giulio; Signorelli, Diego; Simonelli, Ilaria; De Campora, Luca; Mazzarella, Giorgio; Mecozzi, Antonella; Pianelli, Curzio; Camaioni, Angelo; Catalano, Piera; Pasqualetti, Patrizio; Fabiano, Alfredo; Radici, Marco; Marmiroli, Luca; Corsi, Domenico Cristiano.
In: Oncology, Vol. 89, 18.09.2015, p. 227-234.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation
AU - Ciaparrone, Marco
AU - Caspiani, Orietta
AU - Bicciolo, Giulio
AU - Signorelli, Diego
AU - Simonelli, Ilaria
AU - De Campora, Luca
AU - Mazzarella, Giorgio
AU - Mecozzi, Antonella
AU - Pianelli, Curzio
AU - Camaioni, Angelo
AU - Catalano, Piera
AU - Pasqualetti, Patrizio
AU - Fabiano, Alfredo
AU - Radici, Marco
AU - Marmiroli, Luca
AU - Corsi, Domenico Cristiano
PY - 2015/9/18
Y1 - 2015/9/18
N2 - Objective: ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Methods: ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121). Results: High ERCC1 expression was observed in 36 (75%) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95% CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95% CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95% CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95% CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95% CI, 1.27-71.35; p = 0.028). Conclusions: This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation.
AB - Objective: ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Methods: ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121). Results: High ERCC1 expression was observed in 36 (75%) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95% CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95% CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95% CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95% CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95% CI, 1.27-71.35; p = 0.028). Conclusions: This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation.
KW - Adjuvant concurrent chemoradiation
KW - Cisplatin
KW - ERCC1
KW - Head and neck cancer
KW - Squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84942836469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942836469&partnerID=8YFLogxK
U2 - 10.1159/000430447
DO - 10.1159/000430447
M3 - Article
C2 - 26066774
AN - SCOPUS:84942836469
VL - 89
SP - 227
EP - 234
JO - Oncology
JF - Oncology
SN - 0030-2414
ER -